The rising of global geriatric population has contributed to increased prevalence of
dementia. Dementia is a neurodegenerative disease, which is characterized by progressive …

ABSTRACT Introduction: The prevalence of Alzheimer's disease (AD) continues to rise,
while treatment options for cognitive impairment are limited. Acetylcholinesterase inhibitors …

Cholinergic adverse effects of acetylcholinesterase inhibitors (AChEIs) are caused by their
central and peripheral pharmacological actions on a variety of organ tissues …

Background There is no cure for dementia, and no treatments exist to halt or reverse the
course of the disease. Treatments are aimed at improving cognitive and functional …

Current pharmacological therapy for Alzheimer's disease (AD) includes the cholinesterase
inhibitors (ChEIs) donepezil, rivastigmine, and galantamine and the N-methyl d-aspartate …

The use of multi drug regimens among the elderly population has increased tremendously
over the last decade although the benefits of medications are always accompanied by …

Objectives To evaluate the cardiovascular (CV) effects of acetylcholinesterase inhibitors
(AChEIs) in individuals with dementia Design Systematic review and meta‐analysis. Setting …

Acetylcholinesterase inhibitors (ChEI) are the global standard of care for the symptomatic
treatment of Alzheimer's disease (AD) and show significant positive effects in …

Background: Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer's
disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and …

The 'second-generation'cholinesterase inhibitors (ChEIs), donepezil, galantamine and
rivastigmine, are a class of medications that are currently approved for the treatment of mild …